Article
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Cancer immunology research - 1 Jan 2017
Mosely Suzanne I S, Prime John E, Sainson Richard C A, Koopmann Jens-Oliver, Wang Dennis Y Q, Greenawalt Danielle M, Ahdesmaki Miika J, Leyland Rebecca, Mullins Stefanie, Pacelli Luciano, Marcus Danielle, Anderton Judith, Watkins Amanda, Coates Ulrichsen Jane, Brohawn Philip, Higgs Brandon W, McCourt Matthew, Jones Hazel, Harper James A, Morrow Michelle, Valge-Archer Viia, Stewart Ross, Dovedi Simon J, Wilkinson Robert W
Abstract excerpt
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models is not fully understood, impeding appropriate preclinical model selection for target validation, and ultimately hindering drug development. Across a panel of commonly used murine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
